Tutor Lesson

Severe Acute Respiratory Syndrome Coronavirus 2, abbreviated SARS-CoV-2, is the virus responsible for Coronavirus Disease 2019, or COVID-19. This lesson uses SARS-CoV-2 as the virus name.

At the time described, roughly 75,000 infections had been reported. About 1,000 were outside China, including more than 500 aboard a cruise ship near Japan. Because most cases remained in China, the World Health Organization classified the event as an epidemic while recognizing its capacity to become a pandemic.

• The genome is single-stranded RNA.
• A membrane encloses the RNA.
• Spike proteins project from the surface. Their crown-like appearance explains the name coronavirus because corona is Latin for crown.
• The spikes help the virus attach to human cells.

Coronaviruses commonly begin in animals such as bats or rodents. Human infection may follow passage through an intermediary host, including a camel, cow, or civet cat, before transmission among people occurs.

When only a few cases were reported, three were already international. Imperial College London combined that signal with more than 3,300 daily departures from Wuhan, its population of about 11 million, an airport serving 19 million, and an estimated eight-day incubation period. It projected more than 2,000 infections, well above the contemporary official count. A later projection reached 20,000, and reported cases attained that level on February 4.

• In early December or early January, China notified the WHO about the respiratory-illness outbreak.
• During January, SARS-CoV-2 was identified as the cause. China released its gene sequence publicly, allowing laboratories worldwide to use it.
• The first reported U.S. case occurred on January 20.
• Later in January, Wuhan entered lockdown, selected U.S. airports began screening, and deaths exceeded 100.
• Later in January, the University of Louisville was closely monitoring events. The United States began two-week quarantines, its first such use since smallpox 60 years earlier, and deaths passed 200.
• Around mid-February, China screened the temperatures of departing travelers and shared testing probes and primers.
• China later added radiographic evidence to its case definition. The change produced a one-day increase of 15,000 reported cases and was presented as an appropriate epidemic-tracking practice.

In the lesson's timeframe, reported totals exceeded 75,000: about 74,000 in China, about 1,000 elsewhere, and more than 2,000 deaths. A Johns Hopkins website supplied real-time tracking.

The pooled order is clinically intuitive: breathlessness precedes admission. ARDS at day eight followed by ICU transfer around day ten may reflect limited ICU capacity, leaving severely ill patients on general wards until a bed became available.

Some early chest radiographs offered little diagnostic detail, yet they remained useful research records. The publication that established SARS-CoV-2 as the pneumonia's cause included such images to document radiographic change.

• One patient had no important infiltrates on admission day one but clear ARDS by day two.
• Another patient's admission infiltrates improved across days three, five, and six.
• A 52-year-old man had substantial day-five infiltrates that appeared better by day nineteen.

CT scans gave a more detailed view. Across several patients—including adults aged 65, 66, 53, and 40—the repeated patterns were scattered bilateral infiltrates. These observations agreed with the bilateral infiltrates seen in both endemic-coronavirus and early SARS-CoV-2 groups. During an epidemic, radiographic diagnosis can help identify cases quickly, much as imaging or clinical criteria may assist influenza diagnosis during an outbreak.

In an early study of 139 patients, nearly 48% of infections were acquired in healthcare settings. Some transmission followed missed isolation when patients arrived with diarrhea or other non-respiratory symptoms. An ophthalmologist who warned colleagues about the emerging illness later died, and more than 1,700 healthcare workers were reported infected during the early period.

Because the transmission route was initially uncertain, the CDC used extensive PPE. Once the virus was recognized as SARS-like, guidance for the original SARS informed the recommendation for airborne, droplet, and contact precautions.

Contagiousness must be considered alongside severity. The common cold illustrates high spread with low severity; rabies illustrates extreme severity with limited direct transmission. The highly contagious, highly severe corner of such a plot is empty because a disease there would rapidly produce a devastating pandemic. In this early assessment, SARS-CoV-2 was expected to lie between original SARS, with R₀ near 3 and about 10% mortality, and MERS, with R₀ near 1 and about 35% mortality.

No specific treatment or vaccine was available in the lesson's original context, so management centered on supportive care.

• Relieve symptoms such as fever and cough.
• Monitor the patient's condition closely.
• Give intravenous fluids when hydration is needed.
• Provide oxygen and proceed to intubation with mechanical ventilation when necessary.
• Use a somewhat lower tidal volume than usual, titrate PEEP to oxygenation, and maintain plateau pressure around 30 cmH₂O.

• Experience from the original SARS outbreak indicated that aerosol humidification increased droplet transmission.
• Non-invasive positive-pressure ventilation also increased droplet transmission.
• Moving from a ventilator to manual bag ventilation increased viral aerosolization.
• Ribavirin and ganciclovir were ineffective.

• Oseltamivir
• Lopinavir/ritonavir
• Another protease inhibitor whose name is unclear in the transcript
• Interferon alpha and interferon beta-1b, including beta-1b combined with lopinavir/ritonavir in some studies
• RNA polymerase inhibitors such as remdesivir, which was used for the first U.S. patient and appeared to improve his outcome
• Nitazoxanide and chloroquine

NIAID was developing a vaccine directed at the viral spike proteins.

A spontaneous patient arrival would force a rapid decision about whom to screen, how to apply established isolation and PPE, and what treatment to use. Oseltamivir or lopinavir/ritonavir could be obtained locally, while remdesivir required an Investigational New Drug application and shipment.

A controlled alternative was to receive virus from the first Washington State patient in a sealed vial at a Biosafety Level 3 laboratory. Researchers could then organize preparation rather than react during an emergency.

• Testing work could determine who should be screened and whether cheek swabs, stool, urine, or other body fluids gave the best detection results.
• Prevention research could test a drug called Griffithsin, previously studied for influenza and HIV and reported to cover adenovirus and coronavirus.
• Researchers could also assess remdesivir, other RNA polymerase inhibitors, and additional compounds.
• Work could move from in vitro experiments to in vivo studies in ferrets or rodents and then potentially to clinical trials.